Respiratory physician Lutz Beckert considers chronic obstructive pulmonary disease management, including the prevention of COPD, the importance of smoking cessation and pulmonary rehabilitation, and the lifesaving potential of addressing treatable traits. He also discusses the logic of inhaler therapy, moving from single therapy to dual and triple therapy when indicated, as well as other aspects of management
Giving tamariki broader protection against pneumococcal disease
Giving tamariki broader protection against pneumococcal disease

This article looks at the history of pneumococcal vaccination in New Zealand, including the December 2022 change aimed at reducing the burden of pneumococcal disease
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.
1. World Health Organization. Pneumococcal conjugate vaccines in infants and children under 5
years of age: WHO position paper – February 2019. Weekly epidemiological record
2019;94(8):85–104.
2. Mungall BA, Hoet B, Nieto Guevara J, Soumahoro L. A systematic review of invasive
pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal
conjugate vaccines in children. Expert Rev Vaccines 2022;21(2):201–14
3. Anglemyer A, McNeill A, DuBray K, et al. Invasive pneumococcal disease: concerning trends in
serotype 19A notifications in New Zealand. Clin Infect Dis 2022;74(10):1859–61.
4. ESR. Invasive Pneumococcal Disease Quarterly Report July–September 2022.
5. Eichler N, Reynolds E, Jackson C, et al. Invasive pneumococcal disease and serotype emergence
in the Auckland region during the vaccine era 2009–16. J Prim Health Care 2019;11(1):24–31.